In the monotherapy dose escalation, cohort 5 of the trial's intratumoural (IT) and intravenous (IV) arm are now open with the first patients dosed on 16 January and
Imugene Managing Director & CEO
The multicenter, Phase 1, MAST trial commenced by delivering a low dose of VAXINIA to patients with metastatic or advanced solid tumours who have had at least two prior lines of standard of care treatment. With no safety signals identified to date, the trial has since progressed through the monotherapy dose escalation cohorts as well as the combination study, whereby VAXINIA is administered with well-known checkpoint inhibitor pembrolizumab. The City of Hope-developed CF33 oncolytic virus has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models-1. Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in
The clinical trial is titled 'A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33- hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumours (MAST).' The trial commenced in
Contcat:
Tel: 1.300.288.664
(C) 2024 Electronic News Publishing, source